What Imagion Biosystems’ AU$3.75m raise changes for the MagSense HER2 programme
Imagion Biosystems has converted FDA permission to proceed into funding for a Phase 1b/2 test of whether targeted MRI can improve HER2-positive breast cancer staging.
Medical Devices & Diagnostics